Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001): Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001) (NCT01370694), a na phase 1 study. The primary outcome is Number of Participants Experiencing Clinical and Laboratory Adverse Events (AEs) During MK-8808/CVP Combination Therapy.

2. Clinical Question

Statistically, the record poses a descriptive safety question rather than a comparative-effect question. It identifies a population, a treatment context, and a defined observation period, but it does not identify a control arm against which to estimate a treatment contrast. The separate adverse-event summary reports affected-participant counts for serious and other adverse events in the combination group. Those summaries can describe events recorded in this study, but they do not establish how event frequency would differ under another treatment or in the absence of study treatment.

The study also intended to assess pharmacokinetics and tumor response, as reflected in its listed secondary outcomes. The secondary outcomes include maximum and lowest plasma concentrations for MK-8808 in combination therapy and during single-agent maintenance, as well as clinical tumor response to combination therapy. The registry record does not report those outcome results in the information summarized for this analysis.

3. Trial Design

This was an open-label, single-group phase 1 study of MK-8808 in participants with advanced CD20-positive follicular lymphoma and no prior chemotherapy. The registry record lists enrollment of 7 and records the study status as terminated. It gives a start date of 2011-08-19 and a primary completion date of 2014-12-01. The reason for termination is not reported in the registry record.

The planned treatment evaluation included MK-8808 with cyclophosphamide, vincristine, and prednisolone, as well as MK-8808 as a single agent. The available arm record is titled MK-8808 Combination Therapy. Its description states that participants received MK-8808, cyclophosphamide, and vincristine intravenously on Day 1 of each cycle, with prednisolone orally on Days 1 to 5, for a maximum of 8 cycles. The description is truncated, so further details about treatment conduct are not reported in the registry record.

Allocation is listed as not applicable, masking as none, and the model as single group. These features mean that the posted design does not support a randomized comparison between concurrent groups. A single-group study can describe observations among participants who received the study treatment, but changes over time or event counts cannot by themselves distinguish treatment effects from other explanations, including the underlying condition, other care, or chance variation.

The primary endpoint concerns clinical and laboratory adverse events during combination therapy, with a timeframe from the first dose up to 24 weeks. The defined primary population is all participants who received at least one dose of any study drug. The listed secondary outcomes concern MK-8808 plasma concentrations under combination and maintenance treatment and clinical tumor response. The record lists 7 outcome measures, but a complete set of their results is not reported in the registry record.

The study is labeled phase 1, but details of the trial's statistical plan, any interim analyses, and a trial-specific sample-size justification are not reported in the registry record. The posted planning assumptions elsewhere are illustrative rather than a description of the design used for this single-group study.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: All participants receiving at least one dose of any study drug.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants Experiencing Clinical and Laboratory Adverse Events (AEs) During MK-8808/CVP Combination Therapy, measured over From first dose of combination therapy up to 24 weeks.

The named primary endpoint is the number of participants experiencing clinical and laboratory adverse events during MK-8808/CVP combination therapy. Its observation period begins with the first combination-therapy dose and extends up to 24 weeks. The endpoint population is defined as participants receiving at least one dose of any study drug. The registry definition of an adverse event includes an unfavorable and unintended change in body structure, function, or chemistry, whether or not the event is considered related to study treatment.

A participant count is a descriptive measure of how many people in the defined population experienced an event under the endpoint definition. It differs from an event count: one participant may experience more than one event, but the named endpoint is expressed in participants. The endpoint is relevant to a safety-focused early-phase study because it records adverse events during treatment exposure and a specified observation period. Its definition also makes clear that events are counted regardless of an investigator's view of their relation to treatment.

The registry record does not report a consolidated result for this primary endpoint. It does include separate serious and other adverse-event summaries for the combination group, but those summaries should not automatically be treated as the complete primary-endpoint result. The relationship between those group summaries and the endpoint's full clinical-and-laboratory event definition is not reported in the registry record. Without the endpoint result and a more complete account of event ascertainment, the primary question cannot be answered from a single summary count.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

What does a single-group design estimate?

In a single-group study, outcomes are described among participants who receive the study intervention. Such a design can document events and measurements over the study period, but it does not directly estimate a treatment contrast against a concurrent control group. The observed findings may reflect treatment, the underlying condition, other care, measurement practices, or chance. This limitation is especially important when the question is whether an event rate is higher or lower because of treatment: without a comparison group, the counterfactual outcome under another condition is unavailable.

This record lists allocation as not applicable, masking as none, and a single-group model. Therefore, the adverse-event counts are descriptive observations in the listed combination group. They should not be interpreted as comparative estimates or as proof of causation. Open-label status means that masking is not part of the recorded design; the registry record does not provide further details about how event assessment was conducted.

What is the distinction between participants and events?

A participant-based endpoint counts people who meet an event definition. An event-based summary instead counts occurrences, which can include repeated events in the same person. Those measures answer different questions. The named primary endpoint is a number of participants experiencing adverse events, while the separate group summaries identify affected participants for serious and other adverse events. The record does not state whether people can be represented in both summaries, so the counts cannot be combined to create an overall number of affected participants.

For a binary outcome, each participant can be classified according to whether the defined event occurred during the stated observation period. A proportion can describe the share of the analysis population meeting that definition, but such a quantity depends on a clearly specified numerator and denominator. The record supplies affected-participant and at-risk counts for the separate adverse-event summaries, but it does not give a consolidated primary-endpoint result. No new overall proportion should be inferred from the separate summaries.

How should uncertainty be understood?

A confidence interval is a general statistical tool for expressing uncertainty around an estimate. It describes a range of values compatible with the data under a specified statistical method and its assumptions; it does not guarantee that the true value lies in that range, nor does it address every source of bias. In small studies, uncertainty around event rates can be wide, particularly when events are uncommon. The registry record does not report confidence intervals for the adverse-event summaries, so their precision cannot be assessed from interval estimates in the record.

Descriptive counts remain useful even without inferential statistics: they identify the events recorded and the population in which they were observed. Their interpretation must remain limited to those observations. The absence of an interval or model-based analysis should not be filled in by calculating an unreported estimate, particularly when outcome definitions, overlap, missingness, and analysis procedures are not fully described.

What does the planning illustration represent?

The planning assumptions describe an illustration based on an observed effect, with a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. They state that the effect to detect is a stated fraction of the observed effect. These are planning assumptions, not evidence that the trial itself used a two-arm design: the registry design is single group. The illustration is not an observed-power calculation and does not describe the study's actual enrollment rationale or statistical plan. Its sample-size values, where shown, are planning quantities rather than observed participant counts.

In general, a sample-size calculation asks how much information a future study might need under chosen assumptions about the effect, variability, error rates, and design. Changing those assumptions can change the planned sample size. An illustration built around two equal arms does not transfer directly to a single-group study, and a planning result cannot establish that a completed study had adequate precision. The trial-specific sample-size justification is not reported in the registry record.

Why does over-dispersion matter in general?

Over-dispersion is a general issue in count-data analysis: it occurs when variation in counts exceeds what a chosen model assumes. If a model treats observations as less variable than they are, estimated uncertainty may be too small and statistical evidence may appear stronger than warranted. Modeling choices should therefore reflect the outcome structure and observed variability. The registry record does not report an over-dispersion analysis, a count model, or a statistical analysis plan. Since the primary endpoint is expressed as participants experiencing an event, and the posted information does not give a full event-count dataset, no conclusion about over-dispersion can be drawn from these summaries.

What can be said about statistical testing?

The record lists 0 analyses. It does not report a test statistic, a p-value, a confidence interval, or an adjusted comparison for the primary endpoint in the information. The general meaning of a p-value is the degree of compatibility between observed data and a specified null model, conditional on that model and its assumptions; it is not the probability that a treatment works or that a result occurred by chance. Without a reported analysis and comparator, a significance test cannot establish a treatment effect for this single-group study.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("MK-8808 Combination Therapy")
n      <- c(7)
events <- c(6)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  MK-8808 Combination Therapy  7  6  85.7  42.1  99.6  48.7  97.4  47.3  96.8

11. Multiplicity, Missing Data and Analysis Populations

The registry record lists 7 outcome measures, including the primary safety endpoint and secondary outcomes concerning MK-8808 plasma concentrations and clinical tumor response. When a study evaluates multiple outcomes or multiple analyses, multiplicity is a general concern: the chance of at least one apparently notable result can increase as the number of statistical tests grows. Researchers may address this through a prespecified hierarchy, adjustment procedures, or cautious interpretation. The registry record does not report a multiplicity strategy, adjustment method, or complete statistical analysis plan. It also lists 0 analyses, so no multiplicity-adjusted results are reported.

The primary endpoint population is defined as all participants receiving at least one dose of any study drug. That definition identifies who is intended to contribute to the primary safety endpoint, but the registry record does not report a detailed analysis-population flow or explain how participants with incomplete follow-up were handled. Missing-data methods, reasons for missing observations, and the extent of missing outcome data are not reported in the registry record. It is therefore not possible to assess whether missingness could affect the reported safety summaries.

Interim analyses are not reported in the registry record. The record also does not describe stopping criteria or whether the termination followed a prespecified decision rule. The fact that the study is marked terminated does not identify the reason or indicate that interim statistical monitoring occurred.

These omissions matter because outcome definitions, analysis populations, missing-data handling, and multiplicity procedures help determine how results should be interpreted. Without those details, the posted counts remain descriptive safety summaries rather than fully documented inferential results. No unreported analysis procedure should be assumed.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: femoral neck fracture (14.3%).

The combination-group safety summary lists serious adverse events for 1 participant among 7 at risk and other adverse events for 6 participants among 7 at risk. These are affected-participant counts, not counts of every event occurrence. A listed serious adverse-event term is femoral neck fracture, accompanied by 14.3%. The registry record does not provide further detail about the number of occurrences for each term or the circumstances of the event.

The serious and other categories are presented separately. The record does not say whether the same participant could be included in both categories, so the counts should not be added or interpreted as a total number of people with any adverse event. The serious-event listing also does not, by itself, establish that the event was caused by study treatment. The registry definition of an adverse event includes events whether or not considered related to treatment.

These figures describe events recorded in the study group; they do not compare risks against another treatment or a control group. The record does not explain whether these summaries cover every clinical and laboratory adverse event included in the primary endpoint. For that reason, they should be read as separate safety summaries, not as a substitute for a consolidated primary-endpoint result.

13. What the Result Does, and Does Not, Mean

The posted results establish that the registry contains adverse-event summaries for the MK-8808 Combination Therapy group, including separate counts for serious and other events and a listed serious-event term. They also establish that the named primary safety endpoint has a defined observation period and population. The reported information is descriptive: it records affected participants in the study group and does not include a concurrent control comparison.

The results do not establish how the number of adverse events would compare under another treatment, nor do they establish that any particular event was caused by MK-8808, CVP, or their combination. The primary endpoint description includes events regardless of whether they are considered related to study treatment. A single-group design cannot isolate treatment effects from other possible explanations for observed events.

The registry record does not report a consolidated numerical result for the named primary endpoint, an inferential analysis, or confidence intervals for the safety summaries. It also does not report results for the listed pharmacokinetic and tumor-response outcomes in the information. Outcome names describe what the study intended to assess; they do not convey the observed findings.

The listed enrollment and the adverse-event denominators indicate that interpretation is based on a small group. In general, small samples provide limited precision, particularly for uncommon events, and a few observations can strongly influence descriptive summaries. This does not make the recorded events uninformative, but it limits the strength and scope of conclusions that can be drawn from them.

The record's terminated status is a fact about study status, not an explanation for why the study ended. The reason for termination is not reported in the registry record. It is therefore not possible to infer from status alone whether the decision was related to safety, study conduct, or another factor. Overall, the posted data support a cautious account of recorded adverse events in this group, not a claim about comparative safety, causality, or treatment benefit.

14. Why This Trial Matters Statistically

This study is statistically informative as an example of the distinction between a safety-focused study question and the evidence needed to answer comparative questions. The stated primary hypothesis concerns safety and tolerability, and the primary endpoint counts participants with clinical and laboratory adverse events during combination therapy. Those choices identify what the study sought to observe. They do not, on their own, establish a treatment effect or define how large an event frequency would be acceptable.

The single-group design is central to interpretation. It can document what was observed among participants receiving study treatment, but it cannot provide a randomized comparison with another condition. This matters even when the endpoint is a count rather than a continuous measure: a count can be described precisely as an observation while still offering limited information about the treatment's causal contribution.

The record also illustrates why endpoint reporting needs to distinguish a participant-level outcome from separate adverse-event summaries. The primary endpoint is stated as a number of participants experiencing events, while the posted safety information separates serious from other adverse events. Without a consolidated primary-endpoint result and a description of possible overlap, those summaries cannot be combined into a complete overall endpoint count.

Finally, the record lists pharmacokinetic and tumor-response outcomes alongside safety outcomes, but their results are not reported in the information. A complete interpretation depends not only on what outcomes were planned, but also on the results, analysis population, missing-data handling, and statistical methods. The record's limited inferential detail reinforces the importance of keeping descriptive observations distinct from comparative claims.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

Several limitations specific to this study restrict interpretation. The design is single group, open label, and without masking, with allocation listed as not applicable. There is no concurrent comparator in the registry record, so the reported adverse-event counts cannot estimate a difference between treatment conditions. The design also does not separate the contribution of individual components of the combination regimen.

The enrollment is 7, and the reported serious and other adverse-event summaries each use 7 as the at-risk count. A group of this size provides limited information about uncommon events and about the range of possible event frequencies. The summaries do not include confidence intervals or other measures of precision in the registry record.

The primary endpoint is specified, but a consolidated numerical result for it is not reported. The separate safety summaries do not establish whether they capture all clinical and laboratory events covered by the endpoint or whether the participant groups overlap. The registry record does not report missing-data handling, detailed follow-up completeness, or a full account of the analysis population beyond the endpoint population definition.

The listed secondary outcomes include pharmacokinetic measures and clinical tumor response, but their results are not reported in the information. The statistical analysis plan, multiplicity handling, interim analyses, and trial-specific sample-size justification are also not reported in the registry record. The study is marked terminated, but the reason is not reported. These gaps prevent stronger conclusions about the study's planned analyses, the completeness of outcome reporting, or the reason the study ended.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001) — NCT01370694.
• Registry record last updated 2019-03-15; status last verified 2019-02.
• Results first posted 2015-11-25.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

This registry record describes an open-label, single-group phase 1 study of MK-8808 in participants with advanced CD20-positive follicular lymphoma who had received no prior chemotherapy. Enrollment is listed as 7, and the study status is terminated. The study description planned to assess MK-8808 with CVP and as a single agent; the reported group summary is for MK-8808 Combination Therapy.

The primary endpoint counts participants experiencing clinical and laboratory adverse events during combination therapy from the first dose up to 24 weeks. The record includes separate serious and other adverse-event summaries for the combination group, but does not report a consolidated numerical result for the named primary endpoint. The record lists secondary pharmacokinetic and tumor-response outcomes, but their results are not reported in the information. It also does not report inferential analyses, the reason for termination, or a detailed statistical analysis plan. The available findings are descriptive and have no concurrent control comparison.